Prevalence of chronic HCV infection in EU/EEA countries in 2019 using multiparameter evidence synthesis

Christos Thomadakis; Ilias Gountas; Erika Duffell; Konstantinos Gountas; Benjamin Bluemel; Thomas Seyler; Filippo Maria Pericoli; Irene Kászoni-Rückerl; Ziad El-Khatib; Martin Busch; Irene Schmutterer; Thomas Vanwolleghem; Sofieke Klamer; Els Plettinckx; Laure Mortgat; Dominique Van Beckhoven; Tonka Varleva; Mirjana Lana Kosanovic Licina; Tatjana Nemeth Blazic; Diana Nonković; Fanitsa Theophanous; Vratislav Nemecek; Marek Maly; Peer Brehm Christensen; Susan Cowan; Kristi Rüütel; Henrikki Brummer-Korvenkontio; Cécile Brouard; Gyde Steffen; Amrei Krings; Sandra Dudareva; Ruth Zimmermann; Georgia Nikolopoulou; Zsuzsanna Molnár; Emese Kozma; Magnús Gottfredsson; Niamh Murphy; Loreta A Kondili; Maria Elena Tosti; Anna Rita Ciccaglione; Barbara Suligoi; Raina Nikiforova; Renate Putnina; Ligita Jancoriene; Carole Seguin-Devaux; Tanya Melillo; Anders Boyd; Marc van der Valk; Eline Op de Coul; Robert Whittaker; Hilde Kløvstad; Małgorzata Stępień; Magdalena Rosińska; Cristina Valente; Rui Tato Marinho; Odette Popovici; Mária Avdičová; Jana Kerlik; Irena Klavs; Mojca Maticic; Asuncion Diaz; Julia Del Amo; Josefine Lundberg Ederth; Maria Axelsson; Georgios Nikolopoulos

doi:10.1016/j.lanepe.2023.100792

Prevalence of chronic HCV infection in EU/EEA countries in 2019 using multiparameter evidence synthesis

Christos Thomadakis
, Ilias Gountas (Corresponding Author)
, Erika Duffell
, Konstantinos Gountas
, Benjamin Bluemel
, Thomas Seyler
, Filippo Maria Pericoli
, Irene Kászoni-Rückerl
, Ziad El-Khatib
, Martin Busch
, Irene Schmutterer
, Thomas Vanwolleghem
, Sofieke Klamer
, Els Plettinckx
, Laure Mortgat
, Dominique Van Beckhoven
, Tonka Varleva
, Mirjana Lana Kosanovic Licina
, Tatjana Nemeth Blazic
, Diana Nonković

Fanitsa Theophanous, Vratislav Nemecek, Marek Maly, Peer Brehm Christensen, Susan Cowan, Kristi Rüütel, Henrikki Brummer-Korvenkontio, Cécile Brouard, Gyde Steffen, Amrei Krings, Sandra Dudareva, Ruth Zimmermann, Georgia Nikolopoulou, Zsuzsanna Molnár, Emese Kozma, Magnús Gottfredsson, Niamh Murphy, Loreta A Kondili, Maria Elena Tosti, Anna Rita Ciccaglione, Barbara Suligoi, Raina Nikiforova, Renate Putnina, Ligita Jancoriene, Carole Seguin-Devaux, Tanya Melillo, Anders Boyd, Marc van der Valk, Eline Op de Coul, Robert Whittaker, Hilde Kløvstad, Małgorzata Stępień, Magdalena Rosińska, Cristina Valente, Rui Tato Marinho, Odette Popovici, Mária Avdičová, Jana Kerlik, Irena Klavs, Mojca Maticic, Asuncion Diaz, Julia Del Amo, Josefine Lundberg Ederth, Maria Axelsson, Georgios Nikolopoulos (Corresponding Author)

Research output: Contribution to journal › Article › peer-review

30 Citations (Scopus)

Abstract

BACKGROUND: Epidemiological data are crucial to monitoring progress towards the 2030 Hepatitis C Virus (HCV) elimination targets. Our aim was to estimate the prevalence of chronic HCV infection (cHCV) in the European Union (EU)/European Economic Area (EEA) countries in 2019.

METHODS: Multi-parameter evidence synthesis (MPES) was used to produce national estimates of cHCV defined as: π = π recρ rec + π exρ ex + π nonρ non; π rec, π ex, and π non represent cHCV prevalence among recent people who inject drugs (PWID), ex-PWID, and non-PWID, respectively, while ρ rec, ρ ex, and ρ non represent the proportions of these groups in the population. Information sources included the European Centre for Disease Prevention and Control (ECDC) national operational contact points (NCPs) and prevalence database, the European Monitoring Centre for Drugs and Drug Addiction databases, and the published literature.

FINDINGS: The cHCV prevalence in 29 of 30 EU/EEA countries in 2019 was 0.50% [95% Credible Interval (CrI): 0.46%, 0.55%]. The highest cHCV prevalence was observed in the eastern EU/EEA (0.88%; 95% CrI: 0.81%, 0.94%). At least 35.76% (95% CrI: 33.07%, 38.60%) of the overall cHCV prevalence in EU/EEA countries was associated with injecting drugs.

INTERPRETATION: Using MPES and collaborating with ECDC NCPs, we estimated the prevalence of cHCV in the EU/EEA to be low. Some areas experience higher cHCV prevalence while a third of prevalent cHCV infections was attributed to PWID. Further efforts are needed to scale up prevention measures and the diagnosis and treatment of infected individuals, especially in the east of the EU/EEA and among PWID.

Original language	English
Article number	100792
Journal	The Lancet Regional Health - Europe
Volume	36
DOIs	https://doi.org/10.1016/j.lanepe.2023.100792
Publication status	Published - Jan 2024
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords*

viral hepatis
modeling
Europe
HCV
Hepatitis C
prevalence
elimination
chronic hepatitis

Field of Science*

3.3 Health sciences

Publication Type*

1.1. Scientific article indexed in Web of Science and/or Scopus database

Access to Document

10.1016/j.lanepe.2023.100792Licence: CC BY

Cite this

Thomadakis, C., Gountas, I., Duffell, E., Gountas, K., Bluemel, B., Seyler, T., Pericoli, F. M., Kászoni-Rückerl, I., El-Khatib, Z., Busch, M., Schmutterer, I., Vanwolleghem, T., Klamer, S., Plettinckx, E., Mortgat, L., Van Beckhoven, D., Varleva, T., Kosanovic Licina, M. L., Nemeth Blazic, T., ... Nikolopoulos, G. (2024). Prevalence of chronic HCV infection in EU/EEA countries in 2019 using multiparameter evidence synthesis. The Lancet Regional Health - Europe, 36, Article 100792. https://doi.org/10.1016/j.lanepe.2023.100792

@article{2f5f9e0085244af6a068f06411cc6113,

title = "Prevalence of chronic HCV infection in EU/EEA countries in 2019 using multiparameter evidence synthesis",

abstract = "BACKGROUND: Epidemiological data are crucial to monitoring progress towards the 2030 Hepatitis C Virus (HCV) elimination targets. Our aim was to estimate the prevalence of chronic HCV infection (cHCV) in the European Union (EU)/European Economic Area (EEA) countries in 2019.METHODS: Multi-parameter evidence synthesis (MPES) was used to produce national estimates of cHCV defined as: π = π recρ rec + π exρ ex + π nonρ non; π rec, π ex, and π non represent cHCV prevalence among recent people who inject drugs (PWID), ex-PWID, and non-PWID, respectively, while ρ rec, ρ ex, and ρ non represent the proportions of these groups in the population. Information sources included the European Centre for Disease Prevention and Control (ECDC) national operational contact points (NCPs) and prevalence database, the European Monitoring Centre for Drugs and Drug Addiction databases, and the published literature. FINDINGS: The cHCV prevalence in 29 of 30 EU/EEA countries in 2019 was 0.50\% [95\% Credible Interval (CrI): 0.46\%, 0.55\%]. The highest cHCV prevalence was observed in the eastern EU/EEA (0.88\%; 95\% CrI: 0.81\%, 0.94\%). At least 35.76\% (95\% CrI: 33.07\%, 38.60\%) of the overall cHCV prevalence in EU/EEA countries was associated with injecting drugs.INTERPRETATION: Using MPES and collaborating with ECDC NCPs, we estimated the prevalence of cHCV in the EU/EEA to be low. Some areas experience higher cHCV prevalence while a third of prevalent cHCV infections was attributed to PWID. Further efforts are needed to scale up prevention measures and the diagnosis and treatment of infected individuals, especially in the east of the EU/EEA and among PWID.",

keywords = "viral hepatis, modeling, Europe, HCV, Hepatitis C, prevalence, elimination, chronic hepatitis",

author = "Christos Thomadakis and Ilias Gountas and Erika Duffell and Konstantinos Gountas and Benjamin Bluemel and Thomas Seyler and Pericoli, \{Filippo Maria\} and Irene K{\'a}szoni-R{\"u}ckerl and Ziad El-Khatib and Martin Busch and Irene Schmutterer and Thomas Vanwolleghem and Sofieke Klamer and Els Plettinckx and Laure Mortgat and \{Van Beckhoven\}, Dominique and Tonka Varleva and \{Kosanovic Licina\}, \{Mirjana Lana\} and \{Nemeth Blazic\}, Tatjana and Diana Nonkovi{\'c} and Fanitsa Theophanous and Vratislav Nemecek and Marek Maly and Christensen, \{Peer Brehm\} and Susan Cowan and Kristi R{\"u}{\"u}tel and Henrikki Brummer-Korvenkontio and C{\'e}cile Brouard and Gyde Steffen and Amrei Krings and Sandra Dudareva and Ruth Zimmermann and Georgia Nikolopoulou and Zsuzsanna Moln{\'a}r and Emese Kozma and Magn{\'u}s Gottfredsson and Niamh Murphy and Kondili, \{Loreta A\} and Tosti, \{Maria Elena\} and Ciccaglione, \{Anna Rita\} and Barbara Suligoi and Raina Nikiforova and Renate Putnina and Ligita Jancoriene and Carole Seguin-Devaux and Tanya Melillo and Anders Boyd and \{van der Valk\}, Marc and \{Op de Coul\}, Eline and Robert Whittaker and Hilde Kl{\o}vstad and Ma{\l}gorzata St{\c e}pie{\'n} and Magdalena Rosi{\'n}ska and Cristina Valente and Marinho, \{Rui Tato\} and Odette Popovici and M{\'a}ria Avdi{\v c}ov{\'a} and Jana Kerlik and Irena Klavs and Mojca Maticic and Asuncion Diaz and \{Del Amo\}, Julia and \{Lundberg Ederth\}, Josefine and Maria Axelsson and Georgios Nikolopoulos",

note = "{\textcopyright} 2023 The Author(s).",

year = "2024",

month = jan,

doi = "10.1016/j.lanepe.2023.100792",

language = "English",

volume = "36",

journal = "The Lancet Regional Health - Europe",

issn = "2666-7762",

publisher = "Elsevier Ltd.",

}

Thomadakis, C, Gountas, I, Duffell, E, Gountas, K, Bluemel, B, Seyler, T, Pericoli, FM, Kászoni-Rückerl, I, El-Khatib, Z, Busch, M, Schmutterer, I, Vanwolleghem, T, Klamer, S, Plettinckx, E, Mortgat, L, Van Beckhoven, D, Varleva, T, Kosanovic Licina, ML, Nemeth Blazic, T, Nonković, D, Theophanous, F, Nemecek, V, Maly, M, Christensen, PB, Cowan, S, Rüütel, K, Brummer-Korvenkontio, H, Brouard, C, Steffen, G, Krings, A, Dudareva, S, Zimmermann, R, Nikolopoulou, G, Molnár, Z, Kozma, E, Gottfredsson, M, Murphy, N, Kondili, LA, Tosti, ME, Ciccaglione, AR, Suligoi, B, Nikiforova, R, Putnina, R, Jancoriene, L, Seguin-Devaux, C, Melillo, T, Boyd, A, van der Valk, M, Op de Coul, E, Whittaker, R, Kløvstad, H, Stępień, M, Rosińska, M, Valente, C, Marinho, RT, Popovici, O, Avdičová, M, Kerlik, J, Klavs, I, Maticic, M, Diaz, A, Del Amo, J, Lundberg Ederth, J, Axelsson, M & Nikolopoulos, G 2024, 'Prevalence of chronic HCV infection in EU/EEA countries in 2019 using multiparameter evidence synthesis', The Lancet Regional Health - Europe, vol. 36, 100792. https://doi.org/10.1016/j.lanepe.2023.100792

TY - JOUR

T1 - Prevalence of chronic HCV infection in EU/EEA countries in 2019 using multiparameter evidence synthesis

AU - Thomadakis, Christos

AU - Gountas, Ilias

AU - Duffell, Erika

AU - Gountas, Konstantinos

AU - Bluemel, Benjamin

AU - Seyler, Thomas

AU - Pericoli, Filippo Maria

AU - Kászoni-Rückerl, Irene

AU - El-Khatib, Ziad

AU - Busch, Martin

AU - Schmutterer, Irene

AU - Vanwolleghem, Thomas

AU - Klamer, Sofieke

AU - Plettinckx, Els

AU - Mortgat, Laure

AU - Van Beckhoven, Dominique

AU - Varleva, Tonka

AU - Kosanovic Licina, Mirjana Lana

AU - Nemeth Blazic, Tatjana

AU - Nonković, Diana

AU - Theophanous, Fanitsa

AU - Nemecek, Vratislav

AU - Maly, Marek

AU - Christensen, Peer Brehm

AU - Cowan, Susan

AU - Rüütel, Kristi

AU - Brummer-Korvenkontio, Henrikki

AU - Brouard, Cécile

AU - Steffen, Gyde

AU - Krings, Amrei

AU - Dudareva, Sandra

AU - Zimmermann, Ruth

AU - Nikolopoulou, Georgia

AU - Molnár, Zsuzsanna

AU - Kozma, Emese

AU - Gottfredsson, Magnús

AU - Murphy, Niamh

AU - Kondili, Loreta A

AU - Tosti, Maria Elena

AU - Ciccaglione, Anna Rita

AU - Suligoi, Barbara

AU - Nikiforova, Raina

AU - Putnina, Renate

AU - Jancoriene, Ligita

AU - Seguin-Devaux, Carole

AU - Melillo, Tanya

AU - Boyd, Anders

AU - van der Valk, Marc

AU - Op de Coul, Eline

AU - Whittaker, Robert

AU - Kløvstad, Hilde

AU - Stępień, Małgorzata

AU - Rosińska, Magdalena

AU - Valente, Cristina

AU - Marinho, Rui Tato

AU - Popovici, Odette

AU - Avdičová, Mária

AU - Kerlik, Jana

AU - Klavs, Irena

AU - Maticic, Mojca

AU - Diaz, Asuncion

AU - Del Amo, Julia

AU - Lundberg Ederth, Josefine

AU - Axelsson, Maria

AU - Nikolopoulos, Georgios

PY - 2024/1

Y1 - 2024/1

N2 - BACKGROUND: Epidemiological data are crucial to monitoring progress towards the 2030 Hepatitis C Virus (HCV) elimination targets. Our aim was to estimate the prevalence of chronic HCV infection (cHCV) in the European Union (EU)/European Economic Area (EEA) countries in 2019.METHODS: Multi-parameter evidence synthesis (MPES) was used to produce national estimates of cHCV defined as: π = π recρ rec + π exρ ex + π nonρ non; π rec, π ex, and π non represent cHCV prevalence among recent people who inject drugs (PWID), ex-PWID, and non-PWID, respectively, while ρ rec, ρ ex, and ρ non represent the proportions of these groups in the population. Information sources included the European Centre for Disease Prevention and Control (ECDC) national operational contact points (NCPs) and prevalence database, the European Monitoring Centre for Drugs and Drug Addiction databases, and the published literature. FINDINGS: The cHCV prevalence in 29 of 30 EU/EEA countries in 2019 was 0.50% [95% Credible Interval (CrI): 0.46%, 0.55%]. The highest cHCV prevalence was observed in the eastern EU/EEA (0.88%; 95% CrI: 0.81%, 0.94%). At least 35.76% (95% CrI: 33.07%, 38.60%) of the overall cHCV prevalence in EU/EEA countries was associated with injecting drugs.INTERPRETATION: Using MPES and collaborating with ECDC NCPs, we estimated the prevalence of cHCV in the EU/EEA to be low. Some areas experience higher cHCV prevalence while a third of prevalent cHCV infections was attributed to PWID. Further efforts are needed to scale up prevention measures and the diagnosis and treatment of infected individuals, especially in the east of the EU/EEA and among PWID.

AB - BACKGROUND: Epidemiological data are crucial to monitoring progress towards the 2030 Hepatitis C Virus (HCV) elimination targets. Our aim was to estimate the prevalence of chronic HCV infection (cHCV) in the European Union (EU)/European Economic Area (EEA) countries in 2019.METHODS: Multi-parameter evidence synthesis (MPES) was used to produce national estimates of cHCV defined as: π = π recρ rec + π exρ ex + π nonρ non; π rec, π ex, and π non represent cHCV prevalence among recent people who inject drugs (PWID), ex-PWID, and non-PWID, respectively, while ρ rec, ρ ex, and ρ non represent the proportions of these groups in the population. Information sources included the European Centre for Disease Prevention and Control (ECDC) national operational contact points (NCPs) and prevalence database, the European Monitoring Centre for Drugs and Drug Addiction databases, and the published literature. FINDINGS: The cHCV prevalence in 29 of 30 EU/EEA countries in 2019 was 0.50% [95% Credible Interval (CrI): 0.46%, 0.55%]. The highest cHCV prevalence was observed in the eastern EU/EEA (0.88%; 95% CrI: 0.81%, 0.94%). At least 35.76% (95% CrI: 33.07%, 38.60%) of the overall cHCV prevalence in EU/EEA countries was associated with injecting drugs.INTERPRETATION: Using MPES and collaborating with ECDC NCPs, we estimated the prevalence of cHCV in the EU/EEA to be low. Some areas experience higher cHCV prevalence while a third of prevalent cHCV infections was attributed to PWID. Further efforts are needed to scale up prevention measures and the diagnosis and treatment of infected individuals, especially in the east of the EU/EEA and among PWID.

KW - viral hepatis

KW - modeling

KW - Europe

KW - HCV

KW - Hepatitis C

KW - prevalence

KW - elimination

KW - chronic hepatitis

UR - https://www-webofscience-com.db.rsu.lv/wos/alldb/full-record/WOS:001158132700001

U2 - 10.1016/j.lanepe.2023.100792

DO - 10.1016/j.lanepe.2023.100792

M3 - Article

C2 - 38188273

SN - 2666-7762

VL - 36

JO - The Lancet Regional Health - Europe

JF - The Lancet Regional Health - Europe

M1 - 100792

ER -

Prevalence of chronic HCV infection in EU/EEA countries in 2019 using multiparameter evidence synthesis

Abstract

UN SDGs

Keywords*

Field of Science*

Publication Type*

Access to Document

Other files and links

Fingerprint

Cite this